The recent Health Canada approval of Zepbound, a weight loss drug, for treating obstructive sleep apnea in obese adults, has sparked concerns among experts about potential financial risks for benefits plan sponsors. Joseph Koo, an assistant vice-president at Aon, emphasizes that while Zepbound offers a clinical advancement for a specific group, the continuous positive airway pressure (CPAP) machine remains the most cost-effective first-line treatment for most employees with sleep apnea.
Koo highlights the importance of a targeted approach with Zepbound, suggesting its use for patients who also require weight management or those unable to tolerate CPAP. He argues that Zepbound should not be seen as a broad replacement for CPAP therapy, which is significantly more affordable and effective from the outset.
The financial implications of this approval are significant. Even with maintenance and supply costs considered, treating sleep apnea with CPAP machines is far less costly than the drug costs associated with Zepbound. Koo urges employers to view Zepbound's expanded indication through a cost-effectiveness lens, cautioning against unintended broad coverage of glucagon-like peptide-1 (GLP-1) therapies, which could have perpetual financial implications on plans.
To mitigate financial risks, Koo recommends implementing clear criteria such as documented sleep studies, body mass index thresholds, and prior authorization. He also highlights the challenge of expanded indications, noting that current technology at the pharmacy benefit manager or carrier level may not effectively control costs based on indication. Each new indication opens another door for the same expensive drug to enter the formulary.
In my opinion, this situation raises important questions about the balance between clinical advancements and financial sustainability in healthcare. While Zepbound offers a promising treatment option, its potential impact on plan sponsors' finances cannot be overlooked. It is crucial for stakeholders to carefully consider the long-term implications and ensure that any new treatments are implemented with a well-defined strategy to manage costs effectively.
